Literature DB >> 9148253

Efficacy of a novel hydrogel formulation in human volunteers.

H Mayer1, N von der Ohe.   

Abstract

In a two-period crossover study, 20 subjects without an ocular disease received single doses of either a novel timolol hydrogel (T-Gel 0.1%) or aqueous timolol 0.5% in one eye and placebo in the fellow eye. Diurnal variation curves of intraocular pressure of both eyes were obtained for a 24-hour period. Peak effects up to -30% of the baseline were observed. A statistically significant residual effect was still detectable 24 h after application. The timolol gel had the same efficacy in lowering intraocular pressure as the commercially available aqueous timolol solution with a five times higher strength. Equivalence of treatment effects was statistically proved.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9148253     DOI: 10.1159/000310682

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  3 in total

1.  Improved systemic safety and risk-benefit ratio of topical 0.1% timolol hydrogel compared with 0.5% timolol aqueous solution in the treatment of glaucoma.

Authors:  Hannu Uusitalo; Mika Kähönen; Auli Ropo; Jukka Mäenpää; Gunilla Bjärnhall; Hans Hedenström; Väinö Turjanmaa
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-04-21       Impact factor: 3.117

2.  Comparison of a non-preserved 0.1% T-Gel eye gel (single dose unit) with a preserved 0.1% T-Gel eye gel (multidose) in ocular hypertension and glaucomatous patients.

Authors:  D L Easty; G Nemeth-Wasmer; J-P Vounatsos; B Girard; N Besnainou; P Pouliquen; L Delval; J-F Rouland
Journal:  Br J Ophthalmol       Date:  2006-05       Impact factor: 4.638

Review 3.  Timolol 0.1% in Glaucomatous Patients: Efficacy, Tolerance, and Quality of Life.

Authors:  Letizia Negri; Antonio Ferreras; Michele Iester
Journal:  J Ophthalmol       Date:  2019-05-02       Impact factor: 1.909

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.